Long-Term Impact of Colorectal Cancer Screening
Colorectal cancer (CRC) remains a major health concern worldwide. However, sigmoidoscopy screening benefits are now proven to last for over two decades. A recent randomized trial from Norway provides landmark evidence on long-term outcomes. Researchers followed nearly 100,000 participants to evaluate survival and incidence. Consequently, we now have a clearer picture of how a single intervention impacts life-long health. These findings are especially relevant for clinicians managing aging populations.
Analyzing Sigmoidoscopy Screening Benefits
The 23-year follow-up of the NORCCAP trial reveals vital data. Specifically, men experienced a 1.7 percentage point reduction in colorectal cancer risk. Furthermore, their risk of death from the disease dropped significantly. In contrast, women showed a more modest risk reduction. Therefore, clinicians must consider gender when discussing long-term preventive outcomes. Most importantly, the addition of stool tests did not improve these results. Consequently, a single sigmoidoscopy remains a potent, standalone tool for health. The trial recorded the strongest impact in cases of rectosigmoid cancer.
Clinical Implications for the Indian Context
Colorectal cancer rates are steadily rising in India due to shifting dietary patterns. Currently, screening is not part of a national program in the country. Nevertheless, Indian medical societies often recommend screening for individuals starting at age 45. Sigmoidoscopy offers a cost-effective alternative to colonoscopy in resource-limited settings. Moreover, this procedure requires less intensive preparation and fewer specialized resources. Because the benefits persist for 23 years, a single screen could provide significant value to the Indian healthcare system. Doctors should encourage early detection to reduce the growing burden of advanced-stage cancers.
Frequently Asked Questions
Q1: How long do sigmoidoscopy screening benefits last?
Results from the 23-year NORCCAP trial demonstrate that a once-only sigmoidoscopy provides sustained protection against colorectal cancer for over two decades.
Q2: Is sigmoidoscopy as effective for women as it is for men?
While sigmoidoscopy reduced cancer incidence in women by 11% over 23 years, the study did not find a significant reduction in cancer-related deaths for this group compared to the substantial mortality benefit seen in men.
Q3: Does adding a fecal blood test improve sigmoidoscopy outcomes?
According to the trial results, the addition of a fecal immunochemical test did not provide any extra benefit beyond the results achieved by sigmoidoscopy alone.
References
- Botteri E et al. Twenty-Three-Year Benefits of Sigmoidoscopy Screening for Colorectal Cancer : A Randomized Trial. Ann Intern Med. 2026 May 12. doi: 10.7326/ANNALS-25-05456. PMID: 42114097.
- Agrawal M et al. Screening for Colorectal Carcinoma in India: Real-World Scenario, Pitfalls, and Solutions. South Asian J Cancer. 2025;13(4):229-235.
- Wooldrage K et al. Long-term follow-up of a randomized U.K. study on flexible sigmoidoscopy. Lancet Gastroenterol Hepatol. 2024.